Engineering control in drug delivery
EpiQuil is an Australian company developing dissolving microneedle patches for medicines that are poorly absorbed by mouth, or require an injection.
STAGE
Pre-clinical development
ORIGIN
Sydney, Australia
NEXT STEPS
FIH study, 2027
STATUS
Investigational
OUR COMPANY
Rethinking how medicines are delivered
Many promising medicines face significant delivery challenges. Some are poorly absorbed when taken orally, while others rely on injections to achieve the desired therapeutic effect.
At EpiQuil, we're developing a dissolving microneedle platform designed to overcome these limitations. Our technology uses tiny, biodegradable needles that penetrate the skin's outer barrier and dissolve, releasing the medicine without the need for conventional injections.
TECHNOLOGY
Engineering New Approaches to Drug Delivery
At the intersection of materials science and pharmaceutical engineering, EpiQuil is advancing a dissolving microneedle platform through precision design, formulation development and material innovation.
Every aspect of our research is focused on understanding and refining the technology, from its structural architecture to its pharmaceutical integration.
TECHNOLOGY
One platform, countless possibilities
Complex molecules
A versatile platform for a broad range of complex and high-value therapeutic APIs.
Transdermal engineering
Proprietary formulation and microneedle design to enable efficient skin delivery.
Pharmaceutical development
A partner-ready platform, progressing towards first-in- human studies in 2027.
CONNECT WITH EPIQUIL
Let’s explore
We're always open to conversations with those who share our interest in advancing drug delivery. Whether you're exploring a partnership, investment or collaboration, we'd be pleased to connect.
NEWS
